IncellDx Awarded Patent for Use of CCR5 Antagonist Maraviroc in Treatment of COVID-19

Additional patents directed to the use of CCR5 antagonists pending

SAN CARLOS, Calif.--(BUSINESS WIRE)--IncellDx today announced it has been granted U.S. Patent No. 11,180, 491 by the U.S. Patent and Trademark Office (“USPTO”) for methods of treating coronaviruses including COVID-19 (the “Patent”). This patent underwent expedited review under the USPTO’s COVID-19 Prioritized Examination Pilot Program.

The patent is supported by IncellDx’s studies on the role of CCR5 antagonism in acute COVID-19 and in chronic COVID, also known as long COVID or post-acute sequelae of COVID-19 (PASC). In these studies, including a recent study published in the International Journal of Infectious Diseases, among others, IncellDx demonstrated that CCR5 antagonism normalized immunologic biomarkers such as cytokines and signaling proteins and also restored levels of immune cell subsets.

IncellDx’s Chronic COVID Treatment Center recently partnered with ARISE MD Integrative Medicine & Surgery to clinically evaluate the role of CCR5 antagonists in a randomized, placebo controlled trial as a novel therapeutic approach to treating chronic COVID.

“IncellDx is a pioneer in deploying precision medicine approaches in infectious disease,” said Bruce Patterson, CEO, IncellDx. “Our aim is to develop and apply objective diagnostic criteria, new technologies, and more effective treatment approaches that address the underlying causes of acute and chronic COVID-19.”

About IncellDx

IncellDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company’s innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company launched the Chronic COVID Treatment Center to apply precision medicine approaches to evaluate, characterize and more effectively address chronic COVID.